Publications by authors named "Ryuji Tabata"
Objectives: The objective of this study is to assess the trends in treatment selection for patients with de novo metastatic castration-sensitive prostate cancer in the era of upfront combination therapy.
Methods: This multicenter retrospective study included 595 patients treated with either upfront combination therapy (upfront novel hormonal therapies and taxane-based chemotherapy) or vintage therapy (androgen deprivation therapy with or without bicalutamide) between 2016 and 2021. High tumor burden metastatic disease was defined when a patient met the CHAARTED or LATITUDE criteria.
Background: The benefits of novel androgen receptor axis-targeted agents (ARATs) on oncological outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in real-world settings are unclear.
Methods: This multi-institutional retrospective study included 178 patients with nmCRPC treated between September 2003 and August 2022. Patients were divided into two groups: those who were treated with any novel ARATs, including apalutamide, enzalutamide, darolutamide, and abiraterone acetate, during any line of nmCRPC treatment (novel ARATs group) and those who were not (control group).
Article Synopsis
- Nivolumab plus ipilimumab (NIVO+IPI) is the primary treatment for metastatic renal cell carcinoma (mRCC), with about 40% of patients achieving a lasting response, but 20% show primary resistance to the treatment.
- This study analyzed data from 120 mRCC patients treated with NIVO+IPI from August 2015 to January 2023, focusing on factors linked to primary resistant disease (PRD) and patient outcomes.
- The findings revealed that PRD was associated with significantly worse overall survival, and lymph node metastasis (LNM) was identified as an independent risk factor for developing PRD, suggesting some patients may not benefit from NIVO+IPI therapy.
Objective: To assess the impact of radical nephroureterectomy on postoperative renal function in patients with upper tract urothelial carcinoma (UTUC).
Methods: We retrospectively evaluated 645 patients with UTUC treated with radical nephroureterectomy between January 2000 and May 2022. The primary outcome was the rate of postoperative estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.
Article Synopsis
- The study evaluated two treatment strategies for high-risk prostate cancer: robot-assisted radical prostatectomy (RARP) with extended pelvic lymph-node dissection (ePLND) and RARP with neoadjuvant chemohormonal therapy (NCHT) without ePLND.
- A total of 452 patients were analyzed, revealing that the ePLND group had a significantly higher postoperative complication rate compared to the NCHT group.
- Additionally, the NCHT group showed better biochemical recurrence-free and castration-resistant prostate cancer-free survival rates, suggesting that NCHT may be a safer option; however, further research is needed on the long-term outcomes.
Article Synopsis
- The study investigated how reducing the dose of apalutamide affects skin-related side effects and CRPC-free survival in advanced prostate cancer patients.
- A total of 107 patients were evaluated, finding no significant difference in skin-related adverse events between those on full versus reduced doses, although smaller patients experienced fewer side effects with reduced doses.
- The conclusion suggested that reducing the dose may help minimize skin issues for smaller patients while maintaining similar cancer control outcomes.
[SHORT-TERM SURGICAL AND FUNCTIONAL OUTCOMES AFTER ROBOT-ASSISTED SACROCOLPOPEXY IN A SINGLE INSTITUTION].
Nihon Hinyokika Gakkai Zasshi
January 2022
(Objectives) This study aimed to evaluate the surgical outcomes and functional parameters of lower urinary tract and bowel symptoms in patients who have undergone robot-assisted sacrocolpopexy (RASC) due to pelvic organ prolapse. (Patients and methods) This retrospective study included 110 consecutive RASC cases in the urology department of Ageo Central General Hospital, Japan, from November 2020 to October 2021. The medical records of these patients were retrieved.
View Article and Find Full Text PDFBackground: Guidelines define docetaxel as a first-line therapeutic option for metastatic castration-resistant prostate cancer (mCRPC). However, the role of docetaxel in non-metastatic castration-resistant prostate cancer (nmCRPC) has not been fully investigated. The aim of this retrospective study was to evaluate the potential role of docetaxel in nmCRPC.
View Article and Find Full Text PDF[EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT].
Nihon Hinyokika Gakkai Zasshi
January 2017
(Objective) To determine whether the plakin family proteins periplakin, desmoplakin, plectin, and envoplakin could be markers of urothelial carcinoma of the upper urinary tract. (Materials and methods) Fifty-seven surgical specimens were obtained from patients with urothelial carcinoma of the upper urinary tract, who were admitted to the Jikei University Hospital between April 2000 and December 2005. The expression of plakin family proteins in cancerous and normal tissues was investigated using immunohistochemistry, and its association with clinicopathological parameters was analyzed.
View Article and Find Full Text PDFThe objective of this study was to investigate the impact of the biologically equivalent dose (BED) on treatment outcomes after iodine-125 low-dose-rate brachytherapy (LDR-BT) with or without supplemental external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) for intermediate-risk prostate cancer (PCa). We retrospectively evaluated 292 Japanese patients. The impact of the BED and ADT on treatment outcomes was investigated.
View Article and Find Full Text PDF